Craig Kennedy

CEO

Craig has deep insight into the wound care market combined with a proven track record of building businesses. He served as CEO of MolecuLight, a Canadian wound care start-up that developed and launched an imaging device capable of detecting bacteria in wounds.

He also served as VP, Business Development and Strategy for UK-based Systagenix, an established provider of advanced wound care (AWC) products. When the firm was purchased by Acelity, a global AWC company, Craig was a key player facilitating the acquisition.

More recently, Craig was named a 10 Best Inspiring CEO of 2020 for his global approach, commercial credibility, customer focus, and clear communication across all stakeholder groups.

John Adam

COO

John brings over 20 years of experience in medical device manufacturing having worked in multiple European and Asian countries where he delivered process and transactional improvements across manufacturing, supply chain, quality, and procurement. He is responsible for manufacturing operations, quality, and product development.

John has also worked at Molnlycke as VP of Global Manufacturing, at Systagenix (now operating as Acelity) as VP of Global Operations, and at Teleflex as Director of Strategic Development.

Specialising in Lean manufacturing, Six-Sigma, Kaizen, and process improvement, colleagues across his career continue to praise John for his strong leadership skills. He understands how to nurture individual strengths and talents, ultimately encouraging team members to think strategically, innovate, and take action.

Phil Stewart

Group Financial Controller

As Group Financial Controller, Phil plays a vital role in ensuring the financial stability and success of our organization. His strategic insights and business acumen contribute to our continuous growth and drive successful transformations in the wound care industry.

Phil brings a wealth of expertise in finance, system and process change, strategic planning, project management, and stakeholder engagement. With over 18 years’ experience, Phil is a highly qualified chartered accountant (FCA) since 2004, dedicated to delivering successful transformations for organizations.

Before joining NATROX®, Phil made significant contributions as a Director at Rosaris Ltd, a consultancy specialising in finance and tax management for small to medium-sized businesses, playing a pivotal role in fostering growth for numerous enterprises. Prior to that, Phil served as the Senior Finance Manager at EasyJet, a prominent British airline group with extensive global reach. Phil’s commitment to making a difference in the healthcare sector is evident from his time at the Wellcome Trust, a charitable foundation focused on health research. During his impressive 12-year tenure, Phil’s remarkable abilities within the Finance team were recognized with multiple promotions.

Bringing a positive attitude and a great sense of humour, Phil is renowned among colleagues for his willingness to go above and beyond to achieve shared goals. His expertise in relationship building and strategic planning makes him an invaluable asset to the NATROX® team.

Chris Lyon

VP Sales, North America

Chris is responsible for implementing sales strategy, developing product reimbursement strategy across the USA, and penetrating new market segments to drive organisational growth and profitability. He has a long track record of consistently exceeding revenue targets while maintaining a clear focus on strategy.

Prior to NATROX®, he was the VP of Sales at Imbed Biosciences, a medical device company developing innovative solutions for wound care. He also worked in senior sales and marketing roles at Pure & Clean which develops solutions for the wound care market, Innovacyn which is known for developing innovative technologies for wound healing, and TEI Biosciences which manufacture implantable devices to support soft tissue regeneration.

Nancy Stahulak

VP, Global Marketing

Nancy is a strategic, customer-focused marketing leader with a proven track record for driving top-line growth and long-term market sustainability.

Prior to NATROX®, Nancy worked at Medela, the world’s leading medical vacuum technology manufacturer based in Switzerland. During her tenure there, Nancy held the position of Director of Marketing for the Healthcare Division and was responsible for marketing strategy, sales enablement, and clinical solutions for Negative Pressure Wound Therapy (NPWT), Cardiothoracic surgery, and PVS Airway products. Her work experience also includes marketing executive and leadership positions at GE Healthcare Ultrasound, GE Capital, GE Medical Protective, and hospital networks including Advocate Health and Loyola Health Systems.

Nancy will bring her experience from larger organisations to help scale the business globally. She has a solid understanding of the challenges facing the wound care industry and a deep understanding of our customers.

Dr. Emma Woodmansey

Global Clinical Specialist

Emma is responsible for formulating and implementing the company’s clinical strategy. She also contributes to new product design, risk assessments, and instructions-for-use development, all aimed at improving patient outcomes.

Emma joins the NATROX® team after having served in various clinical and healthcare leadership roles over the past 20 years. Most recently she was Medical Affairs Manager, leading the omnichannel education content for Antivirals, at Pfizer UK. Previously she worked for Smith & Nephew in multiple roles including Clinical Strategy Director and Lead Microbiologist for R&D in their Advanced Wound Care Division using scientific and clinical evidence to frame critical issues and shape consensus.

With her background in the fields of microbiology, infection, and advanced wound care, Emma makes valuable contributions to the company’s chief objective – helping patients with wounds regain their lives as quickly as possible.

Nick Howard

Global Business Unit Director

After successfully commercializing NATROX^® O₂ in the UK market, Nick’s current focus is driving the strategic direction of the NATROX^® Wound Care brand by supporting its global market opportunities and the development of new technologies.

Before joining the company, Nick was Global Category Director for Acelity, managing several market-leading global wound care brands, growing them to a revenue of +$120M.

His career in healthcare spans 24 years and includes roles in the NHS, SCA Hygiene Products (Essity) and healthcare communications, plus international sales & marketing positions for Mölnlycke Healthcare and ConvaTec, leading medical solutions companies.

Sandy Fliri-Marx

Director, Human Resources

Sandy brings +20 years of HR experience, with more than half her career in leading Life Sciences firms such as Amgen, Abcam, and Novartis. She has a strong interest in health care on both a professional and personal level, serving as a volunteer at The Hospice Biographers, and supporting students move from education into employment in Life Sciences with Form the Future.

Sandy has developed successful HR strategies for organizations of varying sizes with locations across the globe. Her role is pivotal for Inotec’s expansion. She is responsible for developing HR strategies and system, managing employee relations and recruiting and onboarding staff.

Bruce Geltman

Director, US Strategic Accounts

Prior to joining Inotec, Bruce was a medical, cardiac device and kidney dialysis services professional with St. Jude Medical/Abbott Vascular, Johnson and Johnson and DaVita, maintaining national sales and corporate accounts responsibilities. Prior to moving into the medical device arena in 2005, Bruce was in the telecommunications industry at Corning, Inc. with responsibilities that ranged from Sales Engineering to VP of Sales and Marketing. Bruce drives organizational relevance partnership & growth via planning, analysis, strategic relationships and decisive execution.

Lamine Guendil

General Manager, Asia

Lamine manages Inotec Asia, our Southeast Asian sales headquarters based in Kuala Lumpur, Malaysia. His team’s focus is to provide innovative therapies for people suffering chronic wounds across the region.

Originally serving as a NATROX^® distributor, after Lamine witnessed the positive healing impact our products had on wounds first-hand, he later decided to join the Inotec family. Lamine brings an intense passion for sales, a strong customer-focus, and a creative approach.

David Fernández

Sales Director, EMEA & LATAM

David brings over 14 years of experience in medical devices across a range of areas including dental, respiratory, and diagnostic. Although his main experience is in sales, he has also held positions in product marketing, giving him a well-rounded understanding of customer needs.

With a proven track record of setting up distributor networks in the medical device field across EMEA, David plays a pivotal role maximising business opportunities and bringing a stronger overall focus to the EMEA and LATAM regions.

Dr. Thomas Serena, MD FACS FACHM MAPWCA

Chief Medical Officer

Founder and Medical Director of The SerenaGroup®, a group of wound care clinics, Dr. Serena is a vascular surgeon and long-time proponent of hyperbaric oxygen therapy. The internationally recognised expert in the field of wound healing has been the lead or Principal Investigator in over 100 clinical trials. He has a vast knowledge of oxygen therapy and understands its positive impact on chronic wounds.

Dr. Serena has published more than 200 papers and given more than 1,000 lectures worldwide. His well-decorated tenure includes past-President of the Association for the Advancement of Wound Care (AAWC) and the American Professional Wound Care Association, former board member of the Wound Healing Society, and also Vice-President of the American College of Hyperbaric Medicine. He has also developed a diagnostic technique to collect proteases from chronic wounds, called The Serena Technique©.

Dr. Gregory Schultz

Chief Scientific Officer

Dr. Schultz is Professor Emeritus at the University of Florida where he served as Director of the Institute for Wound Research and Professor of Obstetrics and Gynecology. His extensive research primarily focuses on the regulators of normal wound healing and understanding the role bacterial biofilms and proteases play in impairing wound healing. Dr Schultz has authored or co-authored over 400 publications that have been cited over 23,000 times. He has received $38 million in grant support as a principal- or co-investigator, is an inventor on 36 patents, and was elected a Fellow of the National Academy of Inventors. He served as President of the Wound Healing Society and served on the National Pressure Injury Advisory Panel.

Dr. Windy Cole, DPM

Director, Global Medical Affairs

Dr. Cole has been a practising physician in wound care for over 22 years. She is an adjunct professor and Director of Wound Care Research at Kent State University College of Podiatric Medicine. Board certified by the American Board of Foot and Ankle Surgery and the American Board of Wound Management, Dr. Cole has published numerous peer-reviewed and industry articles and is a sought-after speaker worldwide. She is also a feature writer for Podiatry Management, Today’s Wound Clinic, and a contributing writer for Podiatry Today.

She has been a dedicated wound care advocate for two decades with interests focused on medical education, diabetic foot care, wound care, limb salvage, & clinical research. Her passion to help others has led her to participate in humanitarian efforts including a medical mission to Jordan in 2018 to aid the large Syrian refugee population seeking asylum from civil war. On the forefront of wound research, she was the 2020 World Union of Wound Healing Silver Medal Award recipient for her work in Technology-Driven Research and the 2022 recipient of the Kaplan-Kanat Memorial Lecture Award.

She holds a bachelor’s degree in biology from the University of Cincinnati where she graduated summa cum laude. She is also an honour graduate of Kent State University College of Podiatric Medicine.

Professor Keith Harding

Advisor

World renown as “Godfather of Wound Care,” the highly acclaimed professor has a longstanding interest in wound healing. His clinical practice focusses exclusively on treating patients with wound healing problems with a wide range of aetiologies. He has held numerous external professorial appointments at universities across the UK, Australia, and Singapore. Editor-in-Chief of the International Wound Journal, Prof. Harding has written extensively about wound healing, having authored over 600 publications and written several chapters and books.

Appointed the first Director of the Wound Healing Research Unit in 1991, Prof. Harding went on to serve as Dean of Clinical Innovation at Cardiff University from 2013 to 2018. He was quickly appointed to Medical Director of the Welsh Wound Innovation Centre in 2014, and later appointed as Senior Advisor for Clinical Innovation for Cardiff & Vale University Health Board in 2021.

Prof. Harding has received numerous awards throughout his career, most notably, a total of £200M of grant funding for developing clinical innovation in wound healing. Awarded the CBE in the New Year Honours list in 2013 for Services to Medicine and Health Care, later that year he received £4.2M to establish the Welsh Wound Innovation Initiative, which enabled the creation of the first clinically-focused wound healing centre in the world. In 2014, he was awarded The Learned Society of Wales Fellowship. In 2018, Prof. Harding and his team received a £24M European grant to establish a clinical innovation ecosystem across South Wales. In 2018, he was appointed Senior Clinical Research Director at the A Star Institute in Singapore and a SG$28M wound programme grant.

Despite retiring from academic and clinical practice in the United Kingdom 2022, Prof. Harding continues his passion to advance clinical innovation in wound care. In 2023, he was appointed an independent member of the Cardiff & Vale University Health Board, advises several wound healing and clinical innovation projects, and teaches across Asia, Australia, Europe, and North America.

Dr. Adrian Parton, MBE

Chairman

Adrian Parton is a Director of Objective Imaging Ltd (Hardware Software Automation business), AB-Polyblok Ltd (novel dementia drug), Toxibact Ltd (novel antimicrobial) and Chairman/Owner of Ivy House Country House Hotel. He has a PhD in Molecular Virology and has been in industry for the last 25 years. He has successfully grown technology based businesses from concept through to production and into multi-national businesses.

Michael Clancy

Non-Executive Director

Michael Clancy has 35 years’ experience in marketing, sales and general management within European medical devices with specialist knowledge and experience within the medical beds, pressure redistribution and wound care sectors. He is currently non-executive director at Medstrom Ltd and Inotec AMD Limited.

Pierre Socha

Non-Executive Director

Pierre Socha is an early-stage technology investor with Amadeus Capital Partners. He invests in digital health, medical technologies, autonomous systems, augmented reality, cyber security and artificial intelligence. He currently sits on the boards of Doctify, Repositive, Lumeon, PhoreMost and Congenica.